Vitrafy Life Sciences Ltd. · ASX:VFY

Vitrafy Life Sciences — Shareholder Meeting (November 2026)

39 slides from Vitrafy Life Sciences's shareholder meeting presentation, Nov 17, 2026

  1. Slide 1: 2026 Annual General Meeting – Addresses and Presentation

    ASX ANNOUNCEMENT 17 November 2026 For personal use only 2026 Annual General Meeting – Addresses and Presentation Vitrafy Life Sciences Limited (ASX: VFY), (Vitrafy or Company) attaches in accordance with ASX Listing Rule 3.13.3, a copy of the addresses by Chair, Leigh Farrell and Managing Director a

  2. Slide 2: Chair's Address: Opening and welcome

    Chair’s Address Opening and welcome For personal use only Good afternoon, ladies and gentlemen, and welcome to the 2026 Annual General Meeting of Vitrafy Life Sciences Limited. My name is Leigh Farrell, and it is my privilege to address you for the first time as your Chair. I would like to welcome s

  3. Slide 3: Chair's Address: Capital and Discipline

    This strategy of how Vitrafy successfully commercialises our cryopreservation ecosystem is one cryopreservation ecosystem, addressing multiple industries, simultaneously building multiple pathways to recurring revenue – ultimately, delivering long-term shareholder value. For personal use only Capita

  4. Slide 4: Chair's Address: Outlook

    It would be remiss not to acknowledge the foundations of this strategy established by our team in Ballarat. The work of the team to build the technology and approach that positions us so well in a significant global market cannot be underestimated. I thank them for their contributions. For personal

  5. Slide 5: Managing Director and CEO's Address

    Managing Director and CEO’s Address For personal use only Thank you, Leigh. And good afternoon, everyone — here in the room and online. Twelve months ago, at this meeting, we put our Guardion cryopreservation freezer on display and cryopreserved blood platelets live in front of you, in the time it t

  6. Slide 6: CEO's Address: Partnerships and market exposure

    Having exposure to approximately 17% of the blood collection centers in the market provides a clear pathway for scale up as we successfully convert the partnerships to revenue generating contracts. For personal use only Whilst we see blood as our biggest opportunity, cryopreservation has widespread

  7. Slide 7: CEO's Address: Device build rate and U.S. base

    Our build rate has stepped up. We built ten Guardion devices across FY26. In the first quarter of this year alone, we built nine — almost a full year’s output in a single quarter. We have six more forecast to be released this quarter, taking us to around 25 completed. For personal use only Right now

  8. Slide 8: CEO's Address: Financial position and FY27 objectives

    As a result, we are in a strong financial position and now have the financial footing to accelerate our growth. We finished September with $38.3 million in cash and term deposits — around 7.9 quarters of funding at our first-quarter net operating outflow of $4.9 million. We are also exploring non-di

  9. Slide 9: Vitrafy Life Sciences Annual General Meeting

    Vitrafy Life Sciences rsonal use only Pioneering Technology, Preserving Life. Annual General Meeting 17 November 2026 ASX: VFY | vitrafy.com

  10. Slide 10: Vitrafy Board of Directors

    INTRODUCTION Vitrafy Board of Directors rsonal use only Dr Jeannette Vaughan Dr Leigh Farrell Brent Owens Kate Munnings Joughin Webber Non-Executive Chair Managing Director and Non-Executive Director Non-Executive Director Non-Executive Director CEO 2

  11. Slide 11: Agenda

    AGENDA Format of Meeting rsonal use only 1 Chair Address 2 CEO Address 3 Questions and Voting 4 Formal Business of the Meeting 5 General Questions 6 Meeting Close 3

  12. Slide 12: Chair Address

    rsonal use only Chair Address 4

  13. Slide 13: CEO Address: From promise to execution

    rsonal use only C EO A D D RES S From promise to execution.

  14. Slide 14: AGM 2025: Twelve months ago, a promise

    rsonal use only AGM 2025 Twelve months ago, a promise. The first Guardion prototype cryopreserved platelets live on stage — in the time it takes to make a coffee.

  15. Slide 15: Overview: Last year's commitments delivered

    Overview Last year’s commitments to shareholders. Three objectives, all three delivered. rsonal use only 1 2 3 Market Development Products in Market Organisational Capability Blood: Vitalant, Hoxworth and 19 Guardion devices built U.S. leadership team in place Versiti FDA listing close Colorado base

  16. Slide 16: Highlights

    Highlights We delivered on our commitments for FY2026 delivering devices, partners, customers and capital. rsonal use only 0 19 Guardion devices built 0 3 U.S. civilian blood partners, plus the U.S. Army Conversations Contracts First U.S. cell & gene therapy agreement — Charter Medical Aquaculture s

  17. Slide 17: Market Development

    Market Development Great progress in FY26 converting industry curiosity into partnerships across our priority application areas. rsonal use only Blood and blood products Cell and gene therapy Animal reproduction Red blood cells Red blood cells First U.S. cell and gene therapy Global leader in animal

  18. Slide 18: Market Development: Path to recurring revenue

    Market Development Partnerships follows a consistent path from agreement to recurring revenue. rsonal use only 1 2 3 Partner Integration Convert Agreements with leading Deploy Vitrafy technology for Commercial adoption with blood, cell and gene therapy partner validation in their own recurring reven

  19. Slide 19: Product Development: FDA Listing

    Product Development: FDA Listing Guardion listing as a Class II medical device expected in the coming weeks. rsonal use only C o m p lete Well p ro g ressed Well p ro g ressed N ext Gen 1 device & Verification & Plasma testing Guardion Class II GUARDION builds Validation commenced listing D e- riski

  20. Slide 20: Product Development: Device supply roadmap

    Product Development Scaling device supply ahead of demand, then moving manufacturing to the U.S. rsonal use only Guardion device builds Supply roadmap Now Research-use units Deployed with partners and for verification testing. Early 2027 First medical device fleet Additional manufactured devices in

  21. Slide 21: Organisational Capability

    Organisational Capability A U.S.-centred leadership team, with Colorado as our new base of operations. rsonal use only Executive Team U.S. Base of Operations: Colorado Brent Owens Simon Martin Tim Costello Chief Executive Officer Chief Financial Officer Chief Commercial Officer Heather Pidcoke Pierr

  22. Slide 22: Scientific Leadership for Our Next Phase

    Scientific Leadership for Our Next Phase Deep expertise and industry leadership across blood, cell therapy and trauma care. rsonal use only Scientific Advisory Board Transfusion medicine Cell therapy Cell & gene therapy Trauma care Biostatistics Pampee Young Jose Cancelas Folashade Otegbeye Don Jenk

  23. Slide 23: Funding the Next Stage

    Funding the Next Stage Funding supports device manufacturing and the expansion of U.S. operations. rsonal use only Funding Cash Position $32m $38.3m $30m placement at $2.60 in June 2026 Cash and term deposits at 30 September 2026 $2m share purchase plan in July 2026 ~7.9 quarters of funding at the Q

  24. Slide 24: Outlook: Convert. Scale. Build.

    Outlook: Convert. Scale. Build. rsonal use only Convert Scale Build Partner evaluatio ns into G row d evice sup p ly and secure U.S . o rg anisatio n and co m m ercial ad o p tio n and G uard io n’ s m ed ical d evice o p eratio ns, with C o lo rad o as revenue listing o ur b ase Recurring Revenue D

  25. Slide 25: A year ago, we showed you; this year, we proved it

    rsonal use only A Y EA R A G O , W E S H O W ED Y O U W H A T G U A R D IO N C O U L D D O . T H IS Y EA R , W E P R O V ED IT . The technology. The partners. The funding. The team. The most exciting part starts now. 17

  26. Slide 26: Q&A / Voting Procedure Overview

    rsonal use only Q&A / Voting Procedure Overview 18

  27. Slide 27: Meeting Procedure: Online question process

    MEETING PROCEDURE Q&A / Voting Procedure Overview Online Attendees – Question Process rsonal use only 1 To ask a written question select the Q & A icon 2 Type your question in the text box and press the send button 19

  28. Slide 28: Meeting Procedure: Online voting procedure

    MEETING PROCEDURE Q&A / Voting Procedure Overview Online Attendees - Voting Procedure rsonal use only 1 When the poll is open, sign in and click “Go to voting” 2 To vote, select either For, Against or Abstain 3 You will see a vote confirmation 4 To change your vote, click “Go to voting” at any time

  29. Slide 29: Formal Business of the Meeting

    rsonal use only Formal Business of the Meeting 21

  30. Slide 30: Financial Statements and Reports

    FORMAL BUSINESS Financial Statements and Reports Ordinary business rsonal use only To receive and consider the Company’s Financial Statements, Directors’ Further Information Report and Auditor’s Report for the financial year ended 30 June 2026. Simon Martin, Chief Financial Officer of Vitrafy and Ti

  31. Slide 31: Resolution – Adoption of Remuneration Report

    FORMAL BUSINESS Resolution 1 – Adoption of Remuneration Report To consider and, if thought fit, to pass the following resolution as a non-binding ordinary resolution: rsonal use only “That, for the purpose of section 250R(2) of the Corporations Act and for all Further Information other purposes, app

  32. Slide 32: Resolution – Election of Jeannette Joughin as a Director

    FORMAL BUSINESS Resolution 2 – Election of Jeannette Joughin as a Director rsonal use only To consider and, if thought fit, pass as an ordinary resolution: “That, Jeannette Joughin, who was appointed as an addition to the Board Further Information since the last Annual General Meeting of the Company

  33. Slide 33: Resolution – Re-election of Kate Munnings as a Director

    FORMAL BUSINESS Resolution 3 – Re-election of Kate Munnings as a Director rsonal use only To consider and, if thought fit, pass as an ordinary resolution: “That, Kate Munnings, a Director of the Company who retires in Further Information accordance with clause 64.1 of the Company’s Constitution and,

  34. Slide 34: Resolution – Grant of Performance Rights to CEO Brent Owens

    FORMAL BUSINESS Resolution 4 – Grant of Performance Rights to Managing Director and CEO, Brent Owens rsonal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Further Informat

  35. Slide 35: Resolution – Ratification of Prior Issue of Placement Shares

    FORMAL BUSINESS Resolution 5 – Ratification of Prior Issue of Placement Shares rsonal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That, under and for the purposes of Listing Rule 7.4 and for all other Further Information purposes, the prior iss

  36. Slide 36: Resolution – Approval of 10% Placement Facility

    FORMAL BUSINESS Resolution 6 – Approval of 10% Placement Facility To consider and, if thought fit, pass the following resolution as a special resolution: rsonal use only “That, pursuant to and in accordance with Listing Rule 7.1A and for all Further Information other purposes, Shareholders approve t

  37. Slide 37: General Questions

    rsonal use only General Questions 29

  38. Slide 38: Voting Closure and End of Formal Business

    rsonal use only Voting Closure and End of Formal Business 30

  39. Slide 39: Thank you

    Thank you rsonal use only Pioneering Technology, Preserving Life. Vitrafy Life Sciences Limited vitrafy.com ASX: VFY | 17 November 2026 | vitrafy.com

Vitrafy Life Sciences — Shareholder Meeting (November 2026) on 6ix